Low-risk group
Based on current ESMO-ESGO-ESTRO 2016 risk groups, patients with low-risk EC should not undergo LND as part of the staging process(25) (Table 3). In the low-risk group, considering there is a very low (0.8%) associated risk of LN metastasis(26,27), there is a need to consider the short and long-term morbidities of LND(14,24). However, a minority of studies suggest detection of occult LN metastasis is essential for prognosis, as 4.1–5.6% of low-risk EC patients may have LN metastasis(13,28). LNs are one of the most common sites of relapse, with ∼90% patient mortality(29). LND can provide better prognostic information on patients with low-risk EC at risk of disease recurrence, improving outcomes(29).